These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

517 related articles for article (PubMed ID: 20168271)

  • 21. Intravitreal bevacizumab for the treatment of choroidal neovascularization secondary to angioid streaks: one year of follow-up.
    El Matri L; Kort F; Bouraoui R; Karim B; Chebil A; Chaker N
    Acta Ophthalmol; 2011 Nov; 89(7):641-6. PubMed ID: 21155980
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Results of one-year follow-up examinations after intravitreal bevacizumab administration for chronic central serous chorioretinopathy.
    Inoue M; Kadonosono K; Watanabe Y; Kobayashi S; Yamane S; Arakawa A
    Ophthalmologica; 2011; 225(1):37-40. PubMed ID: 20693820
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration.
    Spaide RF; Laud K; Fine HF; Klancnik JM; Meyerle CB; Yannuzzi LA; Sorenson J; Slakter J; Fisher YL; Cooney MJ
    Retina; 2006 Apr; 26(4):383-90. PubMed ID: 16603955
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Short-term effects of intravitreal bevacizumab for subfoveal choroidal neovascularization in pathologic myopia.
    Hernández-Rojas ML; Quiroz-Mercado H; Dalma-Weiszhausz J; Fromow-Guerra J; Amaya-Espinosa A; Solís-Vivanco A; Reyna-Castelán E; Abraham-Marín M; Martínez-Castellanos MA; Aiello LP
    Retina; 2007; 27(6):707-12. PubMed ID: 17621179
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intravitreal bevacizumab for treatment-naive patients with subfoveal occult choroidal neovascularization secondary to age-related macular degeneration: a 12-month follow-up study.
    Costagliola C; Romano M; Corte MD; Perrotta R; Menzione M; Rinaldi M; Semeraro F; Parmeggiani F
    Retina; 2009 Oct; 29(9):1227-34. PubMed ID: 19934817
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intravitreal ranibizumab versus bevacizumab for treatment of myopic choroidal neovascularization.
    Iacono P; Parodi MB; Papayannis A; Kontadakis S; Sheth S; Cascavilla ML; Bandello F
    Retina; 2012 Sep; 32(8):1539-46. PubMed ID: 22922846
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical course of choroidal neovascularization secondary to angioid streaks treated with intravitreal bevacizumab.
    Teixeira A; Mattos T; Velletri R; Teixeira R; Freire J; Moares N; Bonomo PP
    Ophthalmic Surg Lasers Imaging; 2010; 41(5):546-9. PubMed ID: 20795575
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic factors for visual outcome after intravitreal anti-VEGF injection for naive myopic choroidal neovascularization.
    Yoon JU; Kim YM; Lee SJ; Byun YJ; Koh HJ
    Retina; 2012 May; 32(5):949-55. PubMed ID: 22534553
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intravitreal bevacizumab for exudative branching vascular networks in polypoidal choroidal vasculopathy.
    Wakabayashi T; Gomi F; Sawa M; Tsujikawa M; Nishida K
    Br J Ophthalmol; 2012 Mar; 96(3):394-9. PubMed ID: 21719568
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intravitreal bevacizumab (avastin) for choroidal neovascularization secondary to central serous chorioretinopathy, secondary to punctate inner choroidopathy, or of idiopathic origin.
    Chan WM; Lai TY; Liu DT; Lam DS
    Am J Ophthalmol; 2007 Jun; 143(6):977-983. PubMed ID: 17459318
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intravitreal bevacizumab for treatment-naïve subfoveal occult choroidal neovascularization in age-related macular degeneration.
    Furino C; Boscia F; Recchimurzo N; Besozzi G; Cardascia N; Sborgia L; Niro A; Sborgia C
    Acta Ophthalmol; 2009 Jun; 87(4):404-7. PubMed ID: 18782335
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intravitreal bevacizumab in inflammatory ocular neovascularization.
    Mansour AM; Mackensen F; Arevalo JF; Ziemssen F; Mahendradas P; Mehio-Sibai A; Hrisomalos N; Lai TY; Dodwell D; Chan WM; Ness T; Banker AS; Pai SA; Berrocal MH; Tohme R; Heiligenhaus A; Bashshur ZF; Khairallah M; Salem KM; Hrisomalos FN; Wood MH; Heriot W; Adan A; Kumar A; Lim L; Hall A; Becker M
    Am J Ophthalmol; 2008 Sep; 146(3):410-416. PubMed ID: 18619571
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration.
    Bashshur ZF; Bazarbachi A; Schakal A; Haddad ZA; El Haibi CP; Noureddin BN
    Am J Ophthalmol; 2006 Jul; 142(1):1-9. PubMed ID: 16815245
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ranibizumab for choroidal neovascularization associated with adult-onset foveomacular vitelliform dystrophy: one-year results.
    Mimoun G; Caillaux V; Querques G; Rothschild PR; Puche N; Souied EH
    Retina; 2013 Mar; 33(3):513-21. PubMed ID: 23400081
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration at twenty-four months: the Pan-American Collaborative Retina Study.
    Arevalo JF; Sánchez JG; Wu L; Berrocal MH; Alezzandrini AA; Restrepo N; Maia M; Farah ME; Brito M; Díaz-Llopis M; Rodríguez FJ; Reategui G; Iturralde-Iraola J; Udaondo-Mirete P;
    Ophthalmology; 2010 Oct; 117(10):1974-81, 1981.e1. PubMed ID: 20569989
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of intravitreal bevacizumab (Avastin) in neovascular age-related macular degeneration using a treatment regimen based on optical coherence tomography: 6- and 12-month results.
    Leydolt C; Michels S; Prager F; Garhoefer G; Georgopoulos M; Polak K; Schmidt-Erfurth U
    Acta Ophthalmol; 2010 Aug; 88(5):594-600. PubMed ID: 19485959
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of ranibizumab in patients with subfoveal choroidal neovascularization attributable to age-related macular degeneration.
    Rothenbuehler SP; Waeber D; Brinkmann CK; Wolf S; Wolf-Schnurrbusch UE
    Am J Ophthalmol; 2009 May; 147(5):831-7. PubMed ID: 19217019
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Different dosing of intravitreal bevacizumab for choroidal neovascularization because of pathologic myopia.
    Wakabayashi T; Ikuno Y; Gomi F
    Retina; 2011 May; 31(5):880-6. PubMed ID: 21242860
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term outcomes of intravitreal antivascular endothelial growth factor therapy for the management of choroidal neovascularization in pseudoxanthoma elasticum.
    Myung JS; Bhatnagar P; Spaide RF; Klancnik JM; Cooney MJ; Yannuzzi LA; Freund KB
    Retina; 2010 May; 30(5):748-55. PubMed ID: 19996818
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intravitreal ranibizumab for choroidal neovascularization complicating pathologic myopia.
    Lalloum F; Souied EH; Bastuji-Garin S; Puche N; Querques G; Glacet-Bernard A; Coscas G; Soubrane G; Leveziel N
    Retina; 2010 Mar; 30(3):399-406. PubMed ID: 20038864
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.